David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from ...

AD is a neurodegenerative disease characterized by neuronal loss in the cerebral cortex and the formation of extracellular ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over ...

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the ...

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics ...

Jeff Todd, president and CEO of Prevent Blindness, and Donna Fishman, Director of the National Center for Children’s Vision and Eye Health at Prevent Blindness, join David Hutton of Ophthalmology ...

On World Sight Day, leading experts in ophthalmology look at artificial intelligence and how it could impact diagnosing and ...

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – ...

MJH Life Sciences, parent company of Ophthalmology Times, has acquired The EnVision Summit. The meeting, held annually in ...